Search

Your search keyword '"Robotti, Micaela"' showing total 13 results
Start Over Author "Robotti, Micaela"
13 results on '"Robotti, Micaela"'

1. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

2. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

3. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

4. Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

5. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Published
2022
Full Text
View/download PDF

6. Headache onset after vaccination against SARS-CoV-2:a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Subjects
Adverse Event, SARS-CoV-2, COVID-19/prevention & control, Vaccination, adverse event, Headache, Vaccination/adverse effects, COVID-19, Headache/etiology, General Medicine, chadox1, bnt162b2, Anesthesiology and Pain Medicine, SDG 3 - Good Health and Well-being, Humans, BNT162b2, ChAdOx1, Neurology (clinical), BNT162 Vaccine, covid-19, headache, sars-cov-2, vaccination, bnt162 vaccine, humans
Abstract

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.

Published
2022

7. Additional file 1 of Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Author

Castaldo, Matteo, Waliszewska-Prosół, Marta, Koutsokera, Maria, Robotti, Micaela, Straburzyński, Marcin, Apostolakopoulou, Loukia, Capizzi, Mariarita, Çibuku, Oneda, Ambat, Fidel Dominique Festin, Frattale, Ilaria, Gadzhieva, Zukhra, Gallo, Erica, Gryglas-Dworak, Anna, Halili, Gleni, Jusupova, Asel, Koperskaya, Yana, Leheste, Alo-Rainer, Manzo, Maria Laura, Marcinnò, Andrea, Marino, Antonio, Mikulenka, Petr, Ong, Bee Eng, Polat, Burcu, Popovic, Zvonimir, Rivera-Mancilla, Eduardo, Roceanu, Adina Maria, Rollo, Eleonora, Romozzi, Marina, Ruscitto, Claudia, Scotto di Clemente, Fabrizio, Strauss, Sebastian, Taranta, Valentina, Terhart, Maria, Tychenko, Iryna, Vigneri, Simone, Misiak, Blazej, Martelletti, Paolo, and Raggi, Alberto

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

9. Comorbidities of primary headache disorders: a literature review with meta-analysis.

Author

Caponnetto, Valeria, Deodato, Manuela, Robotti, Micaela, Koutsokera, Maria, Pozzilli, Valeria, Galati, Cristina, Nocera, Giovanna, De Matteis, Eleonora, De Vanna, Gioacchino, Fellini, Emanuela, Halili, Gleni, Martinelli, Daniele, Nalli, Gabriele, Serratore, Serena, Tramacere, Irene, Martelletti, Paolo, and Raggi, Alberto

Subjects
HYPERTENSION, META-analysis, SYSTEMATIC reviews, AGE distribution, BACKACHE, SEX distribution, FIBROMYALGIA, DISEASE prevalence, MENTAL depression, ANXIETY, PRIMARY headache disorders, COMORBIDITY, RESTLESS legs syndrome, DISEASE risk factors, DISEASE complications
Abstract

Background: Primary headache disorders are common and burdensome conditions. They are associated to several comorbidities, such as cardiovascular or psychiatric ones, which, in turn, contribute to the global burden of headache. The aim of this study is to provide a comprehensive description of the pooled prevalence of comorbidities of primary headache disorders using a meta-analytical approach based on studies published between 2000 and 2020. Methods: Scopus was searched for primary research (clinical and population studies) in which medical comorbidities were described in adults with primary headache disorders. Comorbidities were extracted using a taxonomy derived from the Global Burden of Disease (GBD) study. We compared prevalence of comorbidities among headache sufferers against general population using GBD-2019 estimates, and compared comorbidities' proportions in clinical vs. population studies, and by age and gender. Results: A total of 139 studies reporting information on 4.19 million subjects with primary headaches were included: in total 2.75 million comorbidities were reported (median per subject 0.64, interquartile range 0.32–1.07). The most frequently addressed comorbidities were: depressive disorders, addressed in 51 studies (pooled proportion 23 %, 95 % CI 20–26 %); hypertension, addressed in 48 studies (pooled proportion 24 %, 95 % CI 22–26 %); anxiety disorders addressed in 40 studies (pooled proportion 25 %, 95 % CI 22–28 %). For conditions such as anxiety, depression and back pain, prevalence among headache sufferers was higher than in GBD-2109 estimates. Associations with average age and female prevalence within studies showed that hypertension was more frequent in studies with higher age and less females, whereas fibromyalgia, restless leg syndrome, and depressive disorders were more frequent in studies with younger age and more female. Conclusions: Some of the most relevant comorbidities of primary headache disorders – back pain, anxiety and depression, diabetes, ischemic heart disease and stroke – are among the most burdensome conditions, together with headache themselves, according to the GBD study. A joint treatment of headaches and of these comorbidities may positively impact on headache sufferers' health status and contribute to reduce the impact of a group of highly burdensome diseases. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results